GLP-1 Marketing Rules After the Enforcement Wave

What triggered the warning letters

On September 9, 2025, FDA and HHS launched a coordinated initiative against misleading direct-to-consumer pharmaceutical advertising. The agency sent thousands of warning letters and roughly 100 cease-and-desist letters in that opening wave, with telehealth sellers of compounded semaglutide and tirzepatide named as a specific target.

The campaign did not stop there. In early March 2026, FDA issued about 30 more warning letters to telehealth companies marketing compounded GLP-1 products, and a third tranche of 25 letters followed in mid-June 2026.

The trigger was not compounding itself. It was marketing that presented compounded products as if they carried the safety, efficacy, and approval status of the branded drugs they imitate.

The claim language FDA cited as violative

The letters quote recurring phrases. Understanding them tells you exactly where the line sits.

FDA also objected to private-label branding, where a clinic or platform sells a compounded product under its own name without disclosing which pharmacy actually compounds it. In the agency's view that obscures sourcing and implies the marketer is the manufacturer.

• Equivalence claims, such as "weekly injectable GLP-1 with the same active ingredient as Ozempic and Wegovy"
• Calling a compounded product a "generic" version of a brand-name drug
• Implying the compounded product is FDA approved, clinically proven, or therapeutically equivalent
• Cost framing such as "often more cost effective" when paired with equivalence language
• Branding that hides the identity of the actual compounding pharmacy

What claim language survives

The compliant standard is plain: statements must be truthful, not misleading, and substantiated. In practice that means describing your program, not the drug's pedigree. You can say you offer medically supervised weight management, that a licensed provider evaluates each patient, and that treatment plans may include prescription medication when clinically appropriate.

You cannot borrow the brand equity of approved drugs. No side-by-side comparisons to Ozempic or Wegovy, no "same active ingredient" framing, no generic language, and no implication of FDA approval. If you dispense compounded product, identify the compounding pharmacy rather than wrapping it in your own label.

FDA's stated position, quoted in legal analysis of the March 2026 letters, is that compounders should not try to circumvent the approval process by mass-marketing these drugs. Marketing that reads like a branded pharmaceutical campaign is the pattern the agency is matching against.

Who is at risk now

Enforcement has moved well past compounding pharmacies. Telehealth platforms, online sellers, wellness companies, and med spas have all received letters, including many entities that previously assumed they sat outside FDA's regulatory reach.

One signal deserves particular attention from practice owners: FDA issued its first warning letter to a med spa under the Drug Supply Chain Security Act, designating the business a drug "dispenser." That framing pulls ordinary clinics into supply chain compliance obligations most have never mapped.

The legal theories center on misbranding and on the compounding conditions of Sections 503A and 503B of the Food, Drug, and Cosmetic Act. If your ads make drug claims, you are in FDA's lane regardless of what your business card says.

How to audit your GLP-1 marketing this week

Pull every page, ad, email, and social post that mentions a GLP-1. Search for brand names, the word generic, the phrase same active ingredient, and any approval language. Rewrite or remove each instance.

Then check disclosure. If you offer compounded product, name the pharmacy that compounds it, and make clear the product is not FDA approved. Keep substantiation on file for every efficacy statement you retain.

This is also a growth question, not only a legal one. Practices that market their clinical process instead of a drug's borrowed reputation are the ones still advertising after each enforcement wave. Rank and Rejuvenate builds patient acquisition for wellness practices on exactly that footing, compliant claims that still fill the calendar.